Abstract
Human bone marrow mesenchymal stem cell-derived hepatocyte-like cells (hBMSC-HLCs) are a promising alternative to primary human hepatocytes (HHs) for treating liver disease. However, their molecular characteristics remain partially defined. This study clarifies the transcriptome of hBMSC-HLCs using mRNA sequencing, comparing them to undifferentiated hBMSCs and primary HHs. We observed significant gene expression shifts, including the upregulation of 630 genes involved in hepatic metabolism and immune response, and the downregulation of 1,082 genes associated with stemness. Five key biomarkers—TDO2, HP, SERPINA3, LBP, and SAA1—were identified and validated both in vitro and in vivo in a pig model of liver failure. These findings provide a molecular blueprint for hBMSC-HLCs, supporting their future clinical application.
Introduction
End-stage liver failure is a global health crisis with limited treatment options. While primary human hepatocytes (HHs) are the gold standard for cell therapy, their scarcity and difficulty in maintenance necessitate alternative sources. Human bone marrow mesenchymal stem cells (hBMSCs) can be differentiated into hepatocyte-like cells (HLCs), but a comprehensive molecular understanding of these cells is required to ensure safety and efficacy. This paper addresses this gap by defining the transcriptome characteristics of hBMSC-HLCs.
Methods
Researchers isolated hBMSCs from healthy volunteers and confirmed their identity through surface marker profiling and multi-lineage differentiation potential. These cells were then subjected to a 20-day hepatic induction protocol. The team employed whole-genome mRNA sequencing (mRNA-seq) to track transcriptomic changes at Day 0, Day 10, and Day 20, using primary HHs as a benchmark. Bioinformatics tools were used to identify differentially expressed genes (DEGs) and enriched biological pathways. Finally, the findings were validated in vivo by transplanting hBMSCs into a pig model of fulminant hepatic failure (FHF).
Key Results
Morphological and Functional Transition
The differentiation process was marked by a fundamental Mesenchymal-to-Epithelial Transition (MET). Cells shifted from a spindle-like mesenchymal shape to a polygonal epithelial morphology. Functional maturation was evidenced by glycogen accumulation and the expression of classic hepatic markers such as Albumin (ALB) and α-fetoprotein (AFP).
Transcriptomic Shifts and Biomarker Identification
mRNA-seq revealed 630 upregulated genes in HLCs, primarily involved in lipid metabolism and immune signaling. Conversely, 1,082 genes related to stem cell maintenance and cell cycle regulation were downregulated. A key finding was the identification of five specific genes—TDO2, HP, SERPINA3, LBP, and SAA1—that were consistently upregulated both in vitro and in the pig in vivo model. In the pig model, these genes showed a 150-fold increase in expression 7 days post-transplantation, coinciding with liver repair.
Discussion
While hBMSC-HLCs demonstrate a clear hepatic profile, they remain "immature" compared to primary hepatocytes. The transcriptome of D20 cells is significantly closer to HHs than to the original stem cells, yet a gap in full metabolic maturity persists. The identified "Big Five" biomarkers serve as critical quality control markers for future cell manufacturing and clinical monitoring.
Conclusion
hBMSC-HLCs possess a hepatic transcriptome profile and express specific genes in vitro and in vivo. The five upregulated genes identified in this study are potential biomarkers for characterizing hBMSC-HLCs in clinical applications, paving the way for improved stem cell-based therapies for liver disease.
Summary updated